Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough PowerPoint Presentation
Download Presentation
Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough

Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough

195 Vues Download Presentation
Télécharger la présentation

Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. FDA ADVISORY COMMITTEE 5/11/01 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough

  2. OVERVIEW • For many patients, allergies are not appropriately treated without physician management • More data are necessary to support this OTC switch based on unique issues of use • OTC status will decrease access for many patients, and may not decrease use of first-generation anti-histamines

  3. OVERVIEW For many patients, allergies are not appropriately treated without physician management Different types of antihistamine users Short-term vs. chronic Comorbid diseases Cold Use vs. Allergy Disease Management

  4. OVERVIEW • For many patients, allergies are not appropriately treated without physician management • More data are necessary to support this OTC switch based on unique issues of use • OTC status will decrease access for many patients, and may not decrease use of first-generation antihistamines

  5. “Data to support the OTC switch generally comes from the following sources: efficacy trials, safety data, actual use trials, and label comprehension trials…these latter two trials may or may not be needed depending upon whether there are any unique issues related to use, warnings, or directions that need to be tested prior to marketing.” “The switch of a prescription drug to OTC marketing requires a review of the post-marketing safety data and a determination that a consumer can adequately use the product in an OTC setting” FDA OTC Antihistamine Review Team 4/5/01

  6. OVERVIEW • For many patients, allergies are not appropriately treated without physician management • More data are necessary to support this OTC switch based on unique issues of use • OTC status will decrease access for many patients, and may not decrease use of first-generation antihistamines

  7. For many patients, allergies are not appropriately treated without Physician Management 1. Prescription status may be necessary to protect and optimize public health

  8. U.S. Health Care System - 2001 - Evidence-based medicine - Guideline-driven practice - Disease management approach

  9. U.S. Health Care SystemAllergy Management - 2001 • Diagnostic Evaluation • Differentiate allergic disorders from other diseases • Uncover previously unsuspected allergens • Assess comorbid conditions • Environmental Assessment– Antigen Testing • Pharmacologic Therapy • Antihistamines +Rx for Comorbid Conditions • Decongestants • Nasal Steroids • Immunotherapy • Follow-up, Reassessment, Compliance Management

  10. For many patients allergies are not appropriately treated without Physician Management 1. Prescription status may be necessary to protect and optimize public health 2. The safety profiles of the second- generation antihistamines in an OTC setting are not fully known

  11. 2. The safety profiles of the second- generation antihistamines in an OTC setting are not fully known • How often will they be used to treat colds? • How often will patients dose incorrectly? • How many patients will experience exacerbation of untreated or unrecognized co-morbidities? • How often will patients have adverse outcomes as a result of delays in seeking medical care?

  12. For many patients allergies are not appropriately treated without Physician Management 1. Prescription status may be necessary to protect and optimize public health 2. The safety profiles of the second- generation antihistamines in an OTC setting are not fully known 3. Allergies are frequently chronic, complex diseases with serious co-morbidities

  13. Allergies are frequently chronic, complex diseases with Serious Comorbidities Co-morbid conditions associated with allergic rhinitis • Asthma • Sinusitis • Otitis Media Children are seriously affected by allergic rhinitis • 10-40% of school children • Under treatment is related to learning and behavioral problems

  14. Allergies: >50 million Americans Asthma: 15 million Americans 4.8 million children Asthma Prevalence 75% 1980--> 1994 Asthma Deaths 1980 - 11.5/1 million 1995 - 18.0/1 million (5,500 deaths)

  15. Allergic Rhinitis and Asthma Often Co-exist 78% of asthma patients have nasal symptoms 38% of allergic rhinitis patients have asthma 3 million Claritin® Rx’s are co-prescribed with Rx’s for asthma medications (for approximately 1.2M patients with asthma)

  16. Allergy-Asthma Link • Treating allergic inflammation in the nose can reduce asthma symptoms and lower airway hyper-responsiveness.1,2 • Asthmatic patients with Allergic Rhinitis have higher medical costs • In a longitudinal study of 783 students:3 • Resolution of Allergic Rhinitis symptoms correlated with improvement in asthma (p=.0078) • Worsening of Allergic Rhinitis was associated with persistence of asthma 1 Allergy Clin Immonol 1995;95:923-32 2 Allergy Clin Immonol 1996;98:274-82 3 Allergy Proc 1994;15:21-25.

  17. FIRST-GENERATION ANTIHISTAMINES Short-term/episodic use Simple Sx relief for simple allergy patients ?co-morbidity Frequent use in colds SECOND-GENERATION ANTIHISTAMINES Long-Term/chronic use Disease management for Complex patients Frequent co-morbidity Not effective for colds CHANGES IN ALLERGYMANAGEMENT

  18. OTC status may decrease access and not decrease use of first-generation antihistamines Medicaid and poor patients will be unable to afford 2nd-Generation products as OTC’s Patients currently with insurance coverage will make decisions based on out-of-pocket costs Use of sedating antihistamines may well increase

  19. US and CanadianAntihistamine Market Share Source: IMS Health NPA Plus and A.C. Nielsen Note: Calculated using maximum dose per day.

  20. CONCLUSION • Loratadine is most appropriately used as an Rx product • There are unique issues related to use • 1st Generation 2nd Generation • FDA Switch Principles -Labeling must be developed and tested -Actual Use Trials are necessary

  21. CONCLUSION • Loratadine is most appropriately used as an Rx product • There are unique issues related to use • 1st Generation 2nd Generation • FDA Switch Principles -Labeling must be developed and tested -Actual Use Trials are necessary

  22. CONCLUSION • Loratadine is most appropriately used as an Rx product • There are unique issues related to use • 1st Generation 2nd Generation • FDA Switch Principles -Labeling must be developed and tested -Actual Use Trials are necessary

  23. CONCLUSION • Loratadine is most appropriately used as an Rx product • There are unique issues related to use • 1st Generation 2nd Generation • FDA Switch Principles -Labeling must be developed and tested -Actual Use Trials are necessary

  24. ISSUES REQUIRING ASSESSMENT FOR OTC SWITCH • Ability to self-diagnose the condition • Assessment of risk of initial misdiagnosis • Assessment of risk of subsequent misdiagnosis of disease exacerbation or common co-morbid conditions • Assessment of risk of incorrect dosing (voluntary and/or inadvertent) • Assessment of safety in at-risk populations • Label development and comprehension

  25. CONCLUSION • Loratadine is most appropriately used as an Rx product • There are unique issues related to use • 1st Generation 2nd Generation • FDA Switch Principles -Labeling must be developed and tested -Actual Use Trials are necessary

  26. ? Benefit/ Risk Benefit/ Risk + R OTC x

  27. Benefit/ Risk Benefit/ Risk + R OTC x

  28. QUESTIONS